



CASE DM 6904 CNT2

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Jing S. Belfield
Type or print name

Jing S. Belfield
Signature

9/10/03
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

QUAN ET AL.

APPLICATION NO: 10/602,214

FILED: JUNE 24, 2003

FOR:

Mailstop: DD
Commissioner for Patents
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references are of record in parent Application No. 09/099,358, now U.S. Patent 6,339,099, filed June 18, 1998, and copies are available therein. However, applicants are willing to send copies of any or all of these references at the Examiner's request.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-3791



Jing S. Belfield, Ph.D.
Agent for Applicants
Reg. No. 45,914

Date: 9/10/03

Substitute for form 1449A/PTO

SEP 12 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1

of

2

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/602,214 |
| Filing Date | 6/24/03 |
| First Named Inventor | Quan et al. |
| Group Art Unit | |
| Examiner Name | Unknown |
| Attorney Docket Number | DM-6904 CNT 2 |

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|--------------------|-----------------------|----------------------|-----------------------------------|---|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | 5,202,330 | A | E. R. Squibb & Sons, Inc. | 4/13/1993 | |
| | | 5,317,103 | A | Merck Sharp & Dohme Limited | 5/31/1994 | |
| | | 5,342,851 | A | McNeil-PPC, Inc. | 8/30/1994 | |
| | | 5,463,071 | A | Dr. Karl Thomae GmbH | 10/31/1995 | |
| | | 5,616,601 | A | GD Searle & Co | 4/1/1997 | |
| | | 5,681,838 | A | Hoechst AG | 10/28/1997 | |
| | | 5,707,998 | A | Eisai Co., Ltd. | 1/13/1998 | |
| | | 6,020,357 | A | DuPont Pharma. Company | 2/1/2000 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | WO | 9402477 | A | Merck Sharp & Dohme Limited | 2/3/1994 | | |
| | | WO | 9514683 | A | DuPont Merck Pharma. Company | 6/1/1995 | | |
| | | WO | 9518111 | A | DuPont Merck Pharma. Company | 7/6/1995 | | |
| | | WO | 9628427 | A | Berlex Lab., Inc. | 9/19/1996 | | |
| | | WO | 9640143 | A | SmithKline Beecham Corporation | 12/19/1996 | | |
| | | WO | 9723212 | A | DuPont Merck Pharma. Company | 7/3/1997 | | |
| | | WO | 9732583 | A | SmithKline Beecham Corporation | 9/12/1997 | | |

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1996, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/602,214 |
| Filing Date | 6/24/03 |
| First Named Inventor | Quan t al. |
| Group Art Unit | 1624 |
| Examiner Name | Unknown |
| Attorney Docket Number | DM-6904 CNT 2 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document ² | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₃ |
|-----------------------|--------------------------|--------------------------------------|---------------------|--------------------------------------|---|--|--|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | EP | 234830 | A | E. R. Squibb & Sons, Inc. | 9/2/1987 | | |
| | | EP | 236902 | A | E. R. Squibb & Sons, Inc. | 9/16/1987 | | |
| | | EP | 513387 | B | Otsuka Pharm. Co. | 11/19/1992 | | |
| | | EP | 554829 | A | Fujisawa Pharm. Co. | 8/11/1993 | | |
| | | JP | 4247081 | A | Takeda Chem. Ind. Ltd. | 9/3/1992 | Chemical Abstract | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|------------------------|--------------------------|---|----------------|
| | | TIDWELL et al. "Diarylamine derivatives with one or both of the aryl moieties consisting of an indole or indole- like ring. Inhibitors of arginine-specific esterproteases". J. Med. Chem. (1978), 21(7), 613-623. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Substitute for form 1449A/PTO

SEP 12 2003

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/602,214 |
| Filing Date | 6/24/03 |
| First Named Inventor | Quan et al. |
| Group Art Unit | |
| Examiner Name | Unknown |
| Attorney Docket Number | DM-6904 CNT 2 |

U.S. PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | U.S. Patent Document | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------------|--------------------------|----------------------|--------------------------------------|--|--|---|
| | | Number | Kind Code ² (if known) | | | |
| | | 5,202,330 | A | E. R. Squibb & Sons, Inc. | 4/13/1993 | |
| | | 5,317,103 | A | Merck Sharp & Dohme Limited | 5/31/1994 | |
| | | 5,342,851 | A | McNeil-PPC, Inc. | 8/30/1994 | |
| | | 5,463,071 | A | Dr. Karl Thomae GmbH | 10/31/1995 | |
| | | 5,616,601 | A | GD Searle & Co | 4/1/1997 | |
| | | 5,681,838 | A | Hoechst AG | 10/28/1997 | |
| | | 5,707,998 | A | Eisai Co., Ltd. | 1/13/1998 | |
| | | 6,020,357 | A | DuPont Pharma. Company | 2/1/2000 | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|------------------------|--------------------------|-------------------------|---------------------|--------------------------------------|---|--|--|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | WO | 9402477 | A | Merck Sharp & Dohme Limited | 2/3/1994 | | |
| | | WO | 9514683 | A | DuPont Merck Pharma. Company | 6/1/1995 | | |
| | | WO | 9518111 | A | DuPont Merck Pharma. Company | 7/6/1995 | | |
| | | WO | 9628427 | A | Berlex Lab., Inc. | 9/19/1996 | | |
| | | WO | 9640143 | A | SmithKline Beecham Corporation | 12/19/1996 | | |
| | | WO | 9723212 | A | DuPont Merck Pharma. Company | 7/3/1997 | | |
| | | WO | 9732583 | A | SmithKline Beecham Corporation | 9/12/1997 | | |

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

2

Complete if Known

| | |
|------------------------|---------------|
| Application Number | 10/602,214 |
| Filing Date | 6/24/03 |
| First Named Inventor | Quan et al. |
| Group Art Unit | 1624 |
| Examiner Name | Unknown |
| Attorney Docket Number | DM-6904 CNT 2 |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ₆ |
|--------------------|-----------------------|-------------------------|---------------------|-----------------------------------|---|--|---|----------------|
| | | Office ³ | Number ⁴ | Kind Code ⁵ (if known) | | | | |
| | | EP | 234830 | A | E. R. Squibb & Sons, Inc. | 9/2/1987 | | |
| | | EP | 236902 | A | E. R. Squibb & Sons, Inc. | 9/16/1987 | | |
| | | EP | 513387 | B | Otsuka Pharm. Co. | 11/19/1992 | | |
| | | EP | 554829 | A | Fujisawa Pharm. Co. | 8/11/1993 | | |
| | | JP | 4247081 | A | Takeda Chem. Ind. Ltd. | 9/3/1992 | Chemical Abstract | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

| Examiner Initials * | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
|---------------------|-----------------------|---|----------------|
| | | TIDWELL et al. "Diarylaminidene derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esterproteases". J. Med. Chem. (1978), 21(7), 613-623. | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.